Jenny read Experimental Psychology at Oxford University and then moved to the University of Cambridge for post-graduate studies. Her PhD (2005) charted cognitive changes in schizophrenia from first episode to chronic illness, in a range of settings including early intervention and an RCT of antipsychotic medications. Her post-doctoral research has included investigations of the impact on cognition of drugs of abuse, potential for cognitive enhancers in psychosis, and the genetic basis of cognition and psychiatric disorders. During 2007-2008 Jenny was a visiting fellow at the Psychiatric & Neurodevelopmental Genetics Unit at Massachusetts General Hospital, and the Broad Institute of MIT and Harvard. Jenny joined Cambridge Cognition as a Scientific Officer in November 2008. She is an Honorary Research Fellow at the University of Cambridge, and remains involved in ongoing European and American research projects into the genetic basis of normal and abnormal psychological functions.

Natalia trained as a psychologist in Madrid before being awarded a Utrecht Excellence Scholarship to complete an MSc in cognitive neuroscience at the University of Utrecht in the Netherlands. She then moved to the UK to undertake her PhD at the Department of Psychiatry, University of Cambridge as a Gates Cambridge scholar. Her research interest focuses on the use of multi-modal neuroimaging techniques to identify neurobiological markers of psychiatric conditions and associated cognitive deficits. Under the supervision of Professors Barbara Sahakian and Trevor Robbins she combined positron emission tomography (PET) and magnetic resonance imaging (MRI) to investigate the molecular basis of attention deficit/hyperactivity disorder (ADHD) and the neurochemical mechanisms underlying the therapeutic effects of psychostimulant drugs. Natalia is particularly interested in the contribution of neurotransmitter systems to variability in cognitive performance in both health and disease, including ADHD. Much of her work has focused on optimising PET methodology to address these questions at the level of neural networks. Natalia speaks fluent English, Spanish, French, German and Italian.

Dr Rock read Natural Sciences at the University of Cambridge before completing her DPhil in Psychiatry at the University of Oxford. Philippa’s doctoral research was carried out in the Psychopharmacology and Emotion Research Laboratory and employed behavioural, functional imaging, and actigraphic techniques to investigate the changes in emotional processing, cognition, and sleep that are associated with vulnerability to bipolar disorder. Philippa also studied the effects of the atypical antipsychotic quetiapine in healthy volunteers. Her work on quetiapine and risky decision-making earned her a British Association of Psychopharmacology President’s Poster Prize (2010). Philippa is an Honorary Research Fellow at the University of Oxford and remains involved in research focussing on cognition in mood disorders.

Julia graduated with a first class honours degree in Biological Sciences with Psychology from the University of Edinburgh. Following this, she went on to work in a commercial capacity for Deloitte before joining Cambridge Cognition in 2010. Julia is particularly interested in the role that nutrition plays in cognition, both acute and chronic, and has been working with nutraceutical companies to advise on cognitive endpoints. Recently she has been involved in looking at the effects of physical fatigue and stress in long distance endurance rowing, collaborating with Team Indian Ocean 3100.

Professor Robbins is the co-inventor of CANTAB and consults extensively for Cambridge Cognition. He has published nearly five hundred full papers in scientific journals and is in the ISI top 100 most cited neuroscientists. He is a Fellow of the Royal Society, the British Psychological Society and the Academy of Medical Sciences, was President of the British Association of Psychopharmacology (1996-97) and the European Behavioural Pharmacology Society (1992-94) and he won that Society’s inaugural Distinguished Scientist Award in 2001. His research interests span the areas of cognitive neuroscience, behavioural neuroscience and psychopharmacology. His main work focuses on the functions of the frontal lobes of the brain, their connections with other regions, and their relevance to psychiatric and neurological disorders including Parkinson’s and Huntington’s disease, dementia, schizophrenia, depression, drug addiction, obsessive-compulsive disorder and attention deficit/hyperactivity disorder. His lab uses a variety of methods for studying these systems, including sophisticated psychological paradigms for investigating cognitive functions, MRI or PET, and psychopharmacological investigations in patients and healthy volunteers.

Professor Sahakian is the co-inventor of CANTAB and consults extensively for Cambridge Cognition. She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging. She has over 300 publications in scientific journals with specialities including cognition and depression, cognitive enhancement using pharmacological treatments, neuroethics and early detection of Alzheimer's disease. Current research investigates the neurochemical modulation of impulsive and compulsive behaviour in neuropsychiatric disorders, such as unipolar and bipolar depression and attention deficit hyperactivity disorder. Professor Sahakian was one of the first researchers to suggest that attentional dysfunction in Alzheimer's disease could be ameliorated using pharmacotherapy, such as cholinesterase inhibitors. In recognition of her contribution to cognitive neuroscience, she was elected a Fellow of the Academy of Medical Sciences in 2004 and in 2005 she was awarded the Donders Chair in Psychopharmacology at Utrecht University (The Netherlands).

Dr Roiser received a first class degree in Natural Sciences from the University of Cambridge and his PhD, at Cambridge’s Department of Psychiatry, focussed on the effects of monoamine depletions on mood and cognitive performance. He was the first Advanced Scholar on the Cambridge-NIH Health Science Scholars Program and a visiting fellow at the National Institute of Mental Health in Bethesda, MD, before working for 2 years with Eileen Joyce and Karl Friston at the UCL Institute of Neurology as a post-doc, primarily focusing on schizophrenia. He subsequently became a Lecturer and founded the Cognitive Neuropsychiatry group at the Institute of Cognitive Neuroscience in London. Jon’s work aims to understand the neurobiological mechanisms underlying psychiatric symptoms in mood disorders, substance use and schizophrenia. His experiments utilise a range of tools including cognitive psychology, functional neuroimaging, psychopharmacology and genetic studies in patients and healthy volunteers.

Dr Clark has over 10 years experience in academic and clinical laboratories as a research psychologist. His broad research interest is the neural basis of decision-making, with a particular interest in how decision-making is disrupted in forms of psychopathology including addiction and mood disorders. His research combines cognitive psychology, psychophysiology and functional brain imaging. Current focuses include the effects of brain damage on decision-making performance in patients who have had a stroke or a brain tumour, and the effects of pharmacological agents on these cognitive processes, using manipulations that affect the dopamine and serotonin systems.
Luke is a Fellow Commoner and Director of Studies in Experimental Psychology at Trinity Hall and lectures on decision-making, neuropsychology, personality and mental health in the Cambridge Department of Experimental Psychology.

Dr Chamberlain completed his undergraduate, clinical and PhD studies in the University of Cambridge. His primary research interest is in disorders that involve repetitive behaviours, such as obsessive-compulsive disorder, ADHD, and trichotillomania (compulsive hair-pulling). He is internationally known for his studies using cognitive assessment and neuroimaging techniques to explore how drugs exert their effects over psychiatric symptoms and behaviour. These have resulted in a large number of publications in journals including Science and the American Journal of Psychiatry. In addition, Sam is interested in identifying biomarkers that can be used to characterise the likely efficacy of novel therapeutic compounds, and identifying objective 'vulnerability markers' for psychiatric symptoms.

Dr Turner trained as a pharmacist before completing a PhD in psychopharmacology at the University of Cambridge Department of Psychiatry. Her outstanding postgraduate and postdoctoral research into the cognitive effects of psychostimulant medications in schizophrenia, ADHD and healthy volunteers won her honours including the 2006 Times Higher Young Researcher of the Year Award, the British Psychological Society 2007 Award for Outstanding Doctoral Research
Contributions to Psychology, and the 2006 Royal Society Young British Scientist of the Year. Dani’s work in cognitive enhancement has led to a particular interest in the ethics of cognitive enhancement, resulting in her selection as the first ever fellow of the Center for Cognitive Liberty and Ethics.

Dr Elliott is a cognitive neuroscientist with 15 years experience in neuropsychology and functional brain imaging. Rebecca completed a PhD in Cambridge studying neuropsychological function in schizophrenia and depression. She then trained in functional brain imaging at the Wellcome Trust Centre for Neuroimaging in London and is now a Senior Research Fellow in the Neuroscience and Psychiatry Unit, University of Manchester. Her research has focused particularly on emotional and motivational function and how these are disrupted in neuropsychiatric disorders. She has extensive expertise in designing neuropsychological and neuroimaging paradigms to probe cognitive functions relating to clinical symptomatology. Current projects include the neurobiological basis of cognition and craving in opiate addiction, brain imaging correlates of treatment response in depression and the identification of neuropsychological and neuroimaging biomarkers for resilience to stress.

Dr Hutchison is a clinical neuropsychologist with extensive experience in the assessment, diagnosis, management, and treatment of neurocognitive and neurobehavioural disorders. His clinical experience spans the full range of care settings, including neurology and neurosurgery, neurorehabilitation, geriatrics, psychiatry, and paediatrics. Following completion of his doctoral thesis examining HIV-related cognitive impairment at Monash University (Melbourne), Dr Hutchison furthered his neuropsychological career in the UK. This included leading the neuropsychology service at the Defence Medical Rehabilitation Centre (Ministry of Defence) and an internal position as a Scientific Officer with Cambridge Cognition, where he developed expert knowledge of the CANTAB system. He has since returned to Melbourne where he currently works in the Cognitive, Dementia and Memory Services, and in private practice. Dr Hutchison has published in the areas of psychopharmacology, HIV, depression, and cognitive enhancers.

Dr Mehta studied Natural Sciences at Cambridge before completing his PhD at Cambridge’s Department of Psychiatry. He was subsequently awarded an MRC Research Training Fellowship in using positron emission tomography to understand the molecular basis of cognitive function at Hammersmith Hospital London. His work on the role of dopamine in human cognitive function earned him the British Association for Psychopharmacology Vernalis (Young Scientist) Prize in 2005. A Wellcome Trust Value in People Award enabled a move to the London Institute of Psychiatry where he focuses on using functional magnetic resonance imaging methodology to enhance our understanding of drug effects on cognitive function. Current research areas include understanding the role of imaging in drug development, quantitative imaging and novel analysis tools.